Glaxo wins US approval for drug to treat severe asthma
WASHINGTON - The Food and Drug Administration has approved an injectable drug from GlaxoSmithKline PLC to treat severe asthma attacks.
The agency on Wednesday cleared Nucala for patients 12 years and older who cannot control their asthma with more conventional drug options.
According to federal figures, more than 22 million people in the U.S. have asthma, leading to more than 400,000 hospitalizations each year.
Nucala is injected every four weeks by a health care professional in the arm, thigh or abdomen. The genetically engineered antibody is grown in cells from Chinese hamsters and works by reducing levels of white blood cells that contribute to asthma.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Authorities are investigating the shooting death of a local Elvis impersonator
As businesses struggle to hire BREC says they're starting to recover
Deputies find body after recovering car from bayou Friday
Major sticker shock for electric customer faced with $5,000 bill
Murdered teenager remembered by classmates
LSU pitcher Matt Beck gets his moment at the plate
Brusly baseball needs extra innings to win regional series with Jennings.
Southern Athletic Director Roman Banks talks about coaching search
Drew Brees and Sean Payton enjoy the Zurich Classic
Legendary Parkview coach Kenny Guillot passes away at 76